| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/22/2007 | WO2007031338A1 Use of ligands of pparϝ for inducing foetal lung maturity and the prevention of the respiratory-distress syndrome in premature infants |
| 03/22/2007 | WO2007031326A2 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 03/22/2007 | WO2007031312A1 Cox inhibitors |
| 03/22/2007 | WO2007031291A2 Foodstuff additive |
| 03/22/2007 | WO2007031284A1 Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics |
| 03/22/2007 | WO2007031265A2 Combinations comprising a vegf receptor inhibitor and a penetration enhancer |
| 03/22/2007 | WO2007030975A1 New usage of tremella fuciformis heteropolysaccharide or extract thereof |
| 03/22/2007 | WO2007030974A1 New usage of tremella fuciformis heteropolysaccharide or extract thereof |
| 03/22/2007 | WO2007030944A2 Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| 03/22/2007 | WO2007030939A2 Methods of modulating neurotrophin-mediated activity |
| 03/22/2007 | WO2007030934A2 Methods of modulating neurotrophin-mediated activity |
| 03/22/2007 | WO2007030930A1 Methods and compositions for modulating tumor cell activity |
| 03/22/2007 | WO2007030848A2 Non-fluorescent chlorophyll catabolites |
| 03/22/2007 | WO2007016353A3 Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
| 03/22/2007 | WO2007015004A3 Novel crystalline v form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form |
| 03/22/2007 | WO2007013962A3 Rapid onset and short term modafinil compositions and methods of use thereof |
| 03/22/2007 | WO2007012379A3 Use of 3-hydroxycoumarin derivatives |
| 03/22/2007 | WO2007011926A3 Methods for treating and diagnosing complications of premature birth |
| 03/22/2007 | WO2007006926A3 Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
| 03/22/2007 | WO2007006738A3 Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire |
| 03/22/2007 | WO2007005785B1 Thiazoles derivatives as ampk activator |
| 03/22/2007 | WO2007004883A3 A carbohydrate fraction and use thereof for a flat postprandial glucose response |
| 03/22/2007 | WO2007000641A3 Prostaglandin derivatives |
| 03/22/2007 | WO2006134385A3 Anti-inflammatory agents |
| 03/22/2007 | WO2006133339A3 Monoamine re-uptake inhibitors and methods relating thereto |
| 03/22/2007 | WO2006133197A9 Compositions and methods for treating sleep disorders |
| 03/22/2007 | WO2006130472A3 Identification of rac1b as a marker and mediator of matrix metalloproteinase-induced malignancy |
| 03/22/2007 | WO2006130048A3 The method of producing aqueous solution of vitaminized preparation, vitaminized preparation (variants) |
| 03/22/2007 | WO2006129237A3 Novel piperidine carboxylic acid amide derivatives |
| 03/22/2007 | WO2006129120A9 Benzotriazepinone derivatives |
| 03/22/2007 | WO2006127574A3 Method for the treatment of noise phobia in companion animals |
| 03/22/2007 | WO2006127321A3 Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| 03/22/2007 | WO2006124954A3 Inhalable formulations of amphotericin b and methods and devices for delivery thereof |
| 03/22/2007 | WO2006123254A3 Method for determining phytase activity |
| 03/22/2007 | WO2006121995A3 Methods for treating nephrolithiasis |
| 03/22/2007 | WO2006121964A3 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| 03/22/2007 | WO2006121963A3 Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders |
| 03/22/2007 | WO2006121856B1 Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
| 03/22/2007 | WO2006121713A3 Delivery of tigecycline in the presence of heparin |
| 03/22/2007 | WO2006121466A3 Hcv inhibitors |
| 03/22/2007 | WO2006119958A3 Use of flibanserin in the treatment of chronic pain |
| 03/22/2007 | WO2006119884A3 Method for the treatment of drug abuse with flibanserin |
| 03/22/2007 | WO2006119758A3 Dihydroxyphenylalanine derivatives |
| 03/22/2007 | WO2006117609A3 Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3 -receptor ligands |
| 03/22/2007 | WO2006116217A3 Therapeutic bifunctional compounds |
| 03/22/2007 | WO2006115353A9 A novel hydroxamic acid derivative as peptide deformylase inhibitor and manufacturing method thereof |
| 03/22/2007 | WO2006114703A3 Method of administration of (1s,s2) -1- (4 -hydroxyphenyl) -2- (4-hydr0xy-4-phenylpiperidin-1-yl) -1- propano (traxoprodil) |
| 03/22/2007 | WO2006113978A3 Insulins combinations |
| 03/22/2007 | WO2006113853A3 Topiramate compositions for treatment of headache |
| 03/22/2007 | WO2006113468A3 Compositions of novel opioid compounds and method of use thereof |
| 03/22/2007 | WO2006111983A3 NOVEL POLYMORPHIC FORM OF (l-BENZYL-4-[(5,6-DIMETHOXY-l- INDANONE)-2-YL]METHYL PIPERIDINE HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME |
| 03/22/2007 | WO2006110724A3 Method of treating schizophrenia prodrome |
| 03/22/2007 | WO2006106432A8 4-arylpiperidine derivatives and use thereof for preparing a medicament for the treatment of cns disorders |
| 03/22/2007 | WO2006102990A3 Tablet containing steroid hormones |
| 03/22/2007 | WO2006102447A3 Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers |
| 03/22/2007 | WO2006098961A3 Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity |
| 03/22/2007 | WO2006096518A3 Improved gacyclidine formulations |
| 03/22/2007 | WO2006093832A3 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 03/22/2007 | WO2006093518A3 Thienyl compounds for treating virus-related conditions |
| 03/22/2007 | WO2006091847A3 Clopidogrel base suitable for pharmaceutical formulation and preparation thereof |
| 03/22/2007 | WO2006086562A3 Phenylazetidinone derivatives |
| 03/22/2007 | WO2006081994A3 Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperplasia and/or prostate carcinoma |
| 03/22/2007 | WO2006079021A3 Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| 03/22/2007 | WO2006078574A3 Mitotic kinesin inhibitors |
| 03/22/2007 | WO2006072093A3 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone |
| 03/22/2007 | WO2006068742A3 Use of cathepsin inhibitors for reversing or preventing resistance of a cancer cell to a cytotoxic agent |
| 03/22/2007 | WO2006060774A3 Agents that inhibit flavivirus replication and uses thereof |
| 03/22/2007 | WO2006060122A3 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| 03/22/2007 | WO2006058781A3 Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders |
| 03/22/2007 | WO2006053049A3 Herbal composition phy906 and its use in chemotherapy |
| 03/22/2007 | WO2006050585A3 Modulation of nitric oxide synthases by betaines |
| 03/22/2007 | WO2006047195A3 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| 03/22/2007 | WO2006042728A3 Use of stable ammonium liponate salts for the treatment of diabetic and other disorders |
| 03/22/2007 | WO2006039631A3 Methods and compositions for treating renal cell carcinoma related pathologies |
| 03/22/2007 | WO2006016424A8 Preventive and/or therapeutic agent for calcipenia |
| 03/22/2007 | WO2006002909A3 Sphingolipids against pathological processes in lipid rafts |
| 03/22/2007 | WO2005120493A8 Anticancer effect enhancer |
| 03/22/2007 | WO2005115548A3 Treating depressive disorders with carbonic anhydrase activators |
| 03/22/2007 | WO2005115470A3 PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER |
| 03/22/2007 | WO2005111220A3 Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences |
| 03/22/2007 | WO2005107768A3 Method for improving ventilatory efficiency |
| 03/22/2007 | WO2005099719A3 Methods and compositions for the treatment of respiratory syncytial virus |
| 03/22/2007 | WO2005072412A3 Anti-viral therapeutics |
| 03/22/2007 | WO2005072308A3 Cgrp receptor antagonists |
| 03/22/2007 | WO2005058250A3 Methods of administering water-soluble prodrugs of propofol for extended sedation |
| 03/22/2007 | WO2005054264A3 Glycomimetic antagonists for both e- and p-selectins |
| 03/22/2007 | WO2005039550A3 Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
| 03/22/2007 | WO2005033063A3 Melanin concentrating hormone antagonists |
| 03/22/2007 | WO2002011563A8 Food supplement |
| 03/22/2007 | US20070066996 Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury |
| 03/22/2007 | US20070066837 Podophyllotoxin derivatives as antitumor agents |
| 03/22/2007 | US20070066827 Process for the preparation of aryl fused polycyclic lactams |
| 03/22/2007 | US20070066823 CCR9 inhibitors and methods of use thereof |
| 03/22/2007 | US20070066821 Cyclopropyl amines as modulators of the histamine h3 receptor |
| 03/22/2007 | US20070066689 Association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it |
| 03/22/2007 | US20070066688 Cyclopentyl derivatives |
| 03/22/2007 | US20070066687 Amide-based compound, polyolefin resin composition and molded product |
| 03/22/2007 | US20070066686 Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient |
| 03/22/2007 | US20070066685 culturing propionibacterium under anaerobic conditions, in medium containing a carbon source such as lactose, to form 1,4-dihydroxynaphthalene-2-carboxylic acid, having a good flavor, useful for foods, beverages and drugs |
| 03/22/2007 | US20070066684 Preparations composed of specific phorbol derivative and an agent having another anti-HIV effect different in mechanism of action with that of the phorbol derivative; therefore, preparations can exert plural antiviral effects through different mechanisms of action to provide strong antiviral effect |